| Name | FKBP12 PROTAC dTAG-13 |
| Description | FKBP12 PROTAC dTAG-13 is a PROTAC and selective degrader that can be used for target validation during drug discovery by splicing FKBP12 F36V with CRBN and thereby degrading FKBP12 F36V. |
| In vitro | FKBP12 PROTAC dTAG-13 selectively degrades FKBP12^F36V fusion proteins without affecting wild-type FKBP12. In 293T, PATU-8988T, and EOL-1 cells, FKBP12 PROTAC dTAG-13 (500 nM, 4 h) effectively degraded FKBP12^F36V-KRAS^G12V or FKBP12^F36V-ABL1 and suppressed downstream signaling. Dose-dependent degradation was observed from 10 to 500 nM[1]. |
| In vivo | In NOD/SCID mice bearing PATU-8988T FKBP12^F36V-KRAS^G12V xenografts, a single intraperitoneal dose of FKBP12 PROTAC dTAG-13 (35 mg/kg) reduced fusion protein levels in tumors within 2 h, lasting ≥12 h[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 3.3 mg/mL (3.15 mM), Sonication is recommended.
DMSO : 80 mg/mL (76.25 mM), Sonication is recommended.
|
| Keywords | FKBP12 PROTAC dTAG-13 | FKBP-12 PROTAC dTAG-13 | FKBP12 PROTAC dTAG13 | FKBP12 PROTAC dTAG 13 | EpigeneticReaderDomain | Epigenetic Reader Domain | BRD4 |
| Inhibitors Related | Stearamide | L-Leucine | 4-Vinylcyclohexene Dioxide | Resveratrol | N-Hydroxyphthalimide | L-Proline | Metformin | Methyl eugenol | Metformin hydrochloride | (E/Z)-10-Hydroxy-2-decenoic acid | Vepdegestrant | Dihydromyricetin |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | PI3K-AKT-mTOR Compound Library | Bioactive Compound Library | Kinase Inhibitor Library | Multi-Target Compound Library | Post-Translational Modification Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
